MA28038A1 - Thienopyrazoles - Google Patents

Thienopyrazoles

Info

Publication number
MA28038A1
MA28038A1 MA28871A MA28871A MA28038A1 MA 28038 A1 MA28038 A1 MA 28038A1 MA 28871 A MA28871 A MA 28871A MA 28871 A MA28871 A MA 28871A MA 28038 A1 MA28038 A1 MA 28038A1
Authority
MA
Morocco
Prior art keywords
thienopyrazoles
modulable
itk
inhibition
compounds
Prior art date
Application number
MA28871A
Other languages
English (en)
Inventor
John Gerard Jurcak
Matthieu Barrague
Timothy Alan Gillespy
Michael Louis Edwards
Kwon Yon Musick
Philip Marvin Weintraub
Yan Du
Ramalinga M Dharanipragada
Ashfaq Ahmed Parkar
Original Assignee
Aventis Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Inc filed Critical Aventis Pharma Inc
Publication of MA28038A1 publication Critical patent/MA28038A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Les thiénopyrazoles, leur préparation, les compositions pharmaceutiques comprenant ces composés, et leurs utilisations pharmaceutiques dans le traitement d'états pathologiques modulables par l'inhibition des protéines kinases, en particulier de la tyrosine kinase inductible par l'interleukine-2 (ITK).
MA28871A 2003-09-08 2006-03-13 Thienopyrazoles MA28038A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US50115903P 2003-09-08 2003-09-08

Publications (1)

Publication Number Publication Date
MA28038A1 true MA28038A1 (fr) 2006-07-03

Family

ID=34312256

Family Applications (1)

Application Number Title Priority Date Filing Date
MA28871A MA28038A1 (fr) 2003-09-08 2006-03-13 Thienopyrazoles

Country Status (29)

Country Link
US (2) US7518000B2 (fr)
JP (1) JP4879739B2 (fr)
KR (1) KR20060069490A (fr)
CN (1) CN100398545C (fr)
AT (1) ATE468341T1 (fr)
AU (1) AU2004272507B2 (fr)
BR (1) BRPI0414215A (fr)
CA (1) CA2538032C (fr)
CR (1) CR8255A (fr)
DE (1) DE602004027288D1 (fr)
DK (1) DK1682553T3 (fr)
EC (1) ECSP066411A (fr)
ES (1) ES2345257T3 (fr)
HR (1) HRP20100398T1 (fr)
IL (1) IL173916A (fr)
MA (1) MA28038A1 (fr)
ME (1) MEP20908A (fr)
MX (1) MXPA06001827A (fr)
MY (1) MY144339A (fr)
NO (1) NO20061626L (fr)
NZ (1) NZ545421A (fr)
OA (1) OA13252A (fr)
PT (1) PT1682553E (fr)
RS (2) RS51846B (fr)
RU (1) RU2358978C2 (fr)
TN (1) TNSN06058A1 (fr)
TW (1) TWI352705B (fr)
WO (1) WO2005026175A1 (fr)
ZA (1) ZA200601947B (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006101454A1 (fr) * 2005-03-21 2006-09-28 S*Bio Pte Ltd Derives du benzothiophene: preparation et applications pharmaceutiques
WO2007076228A2 (fr) * 2005-12-20 2007-07-05 Boehringer Ingelheim International Gmbh Inhibiteurs de kinases tec
EP2151433A1 (fr) 2008-08-05 2010-02-10 Institut Pasteur Alkoxypyrazoles et leur procédé de préparation
EP2151434A1 (fr) 2008-08-05 2010-02-10 Institut Pasteur Alkoxypyrazoles et leur procédé de préparation
US8299070B2 (en) * 2009-11-25 2012-10-30 Japan Tobacco Inc. Indole compounds and pharmaceutical use thereof
US20130158066A1 (en) * 2011-12-20 2013-06-20 Hoffmann-La Roche Inc. 4-azaindole inhibitors of crac
WO2013153539A1 (fr) 2012-04-13 2013-10-17 Glenmark Pharmaceuticals S.A. Composés tricycliques à titre d'inhibiteurs de kinases tec
CN103467481B (zh) * 2012-06-07 2016-08-31 上海汇伦生命科技有限公司 二氢吡啶类化合物、其组合物、制备方法和用途
TW201414734A (zh) 2012-07-10 2014-04-16 Takeda Pharmaceutical 氮雜吲哚衍生物
WO2014041518A1 (fr) * 2012-09-14 2014-03-20 Glenmark Pharmaceuticals S.A. Composés thiénopyrrole comme inhibiteurs de l'itk
CN103720694A (zh) * 2012-10-11 2014-04-16 韩冰 一类治疗脑性瘫痪的化合物及其用途
CN103772391A (zh) * 2012-10-23 2014-05-07 杨子娇 一类治疗房角狭窄的化合物及其用途
KR101571590B1 (ko) * 2012-11-21 2015-11-25 주식회사 두산 유기 화합물 및 이를 이용하는 유기 전계 발광 소자
EP3060218A4 (fr) 2013-10-25 2017-07-19 Pharmacyclics LLC Méthodes de traitement et de prévention d'une maladie du greffon contre l'hôte
AR099052A1 (es) 2014-01-09 2016-06-29 Takeda Pharmaceuticals Co Derivados de azaindol
WO2016010108A1 (fr) * 2014-07-18 2016-01-21 塩野義製薬株式会社 Dérivés hétérocycliques contenant de l'azote et compositions médicinales le contenant
HK1256718A1 (zh) 2015-08-31 2019-10-04 药品循环有限责任公司 用於治疗多发性骨髓瘤的btk抑制剂组合
US20190298772A1 (en) 2016-11-03 2019-10-03 Juno Therapeutics, Inc. Combination therapy of a t cell-based therapy and a btk inhibitor
EP3787751A1 (fr) 2018-05-03 2021-03-10 Juno Therapeutics, Inc. Polythérapie d'une thérapie par lymphocytes t à récepteur antigénique chimérique (car) et d'un inhibiteur de btk
WO2023139248A1 (fr) * 2022-01-21 2023-07-27 Ecole Polytechnique Federale De Lausanne (Epfl) Inhibiteurs de thioestérases de protéine acyle contre des infections microbiennes
US20250302954A1 (en) 2022-05-11 2025-10-02 Celgene Corporation Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy
WO2024123175A1 (fr) 2022-12-06 2024-06-13 Erasmus University Medical Center Rotterdam Compositions pour le traitement de cancers résistants à la thérapie par blocage de point de contrôle immunitaire

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5654307A (en) * 1994-01-25 1997-08-05 Warner-Lambert Company Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family
US6462036B1 (en) * 1998-11-06 2002-10-08 Basf Aktiengesellschaft Tricyclic pyrazole derivatives
US6297238B1 (en) * 1999-04-06 2001-10-02 Basf Aktiengesellschaft Therapeutic agents
PT1194425E (pt) * 1999-06-23 2005-10-31 Aventis Pharma Gmbh Benzimidazoles substituidos
YU54202A (sh) * 2000-01-18 2006-01-16 Agouron Pharmaceuticals Inc. Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije
US7101884B2 (en) * 2001-09-14 2006-09-05 Merck & Co., Inc. Tyrosine kinase inhibitors
FR2831536A1 (fr) * 2001-10-26 2003-05-02 Aventis Pharma Sa Nouveaux derives de benzimidazoles, leur procede de preparation, leur application a titre de medicament, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteurs de kdr
MXPA04003954A (es) * 2001-10-26 2004-11-29 Aventis Pharma Inc Bencimidazoles.

Also Published As

Publication number Publication date
JP4879739B2 (ja) 2012-02-22
PT1682553E (pt) 2010-07-29
HRP20100398T1 (hr) 2010-09-30
IL173916A (en) 2011-07-31
RU2358978C2 (ru) 2009-06-20
KR20060069490A (ko) 2006-06-21
US20070254937A1 (en) 2007-11-01
TW200519118A (en) 2005-06-16
RS51846B (sr) 2012-02-29
BRPI0414215A (pt) 2006-11-07
CN1849322A (zh) 2006-10-18
CA2538032A1 (fr) 2005-03-24
MEP20908A (en) 2010-06-10
ES2345257T3 (es) 2010-09-20
US7928231B2 (en) 2011-04-19
RU2006111470A (ru) 2007-10-27
TNSN06058A1 (en) 2007-10-03
CR8255A (es) 2006-07-14
ZA200601947B (en) 2007-05-30
DK1682553T3 (da) 2010-08-23
CN100398545C (zh) 2008-07-02
ECSP066411A (es) 2006-09-18
DE602004027288D1 (en) 2010-07-01
ATE468341T1 (de) 2010-06-15
CA2538032C (fr) 2011-01-11
IL173916A0 (en) 2006-07-05
NO20061626L (no) 2006-04-10
AU2004272507B2 (en) 2011-05-12
JP2007505038A (ja) 2007-03-08
WO2005026175A1 (fr) 2005-03-24
OA13252A (en) 2007-01-31
HK1095587A1 (zh) 2007-05-11
AU2004272507A1 (en) 2005-03-24
RS20060162A (sr) 2008-06-05
TWI352705B (en) 2011-11-21
NZ545421A (en) 2010-03-26
MY144339A (en) 2011-08-29
US20100056514A1 (en) 2010-03-04
US7518000B2 (en) 2009-04-14
MXPA06001827A (es) 2006-05-31

Similar Documents

Publication Publication Date Title
MA28038A1 (fr) Thienopyrazoles
BR9914360A (pt) N-aralquilaminotetralinas como ligandos para oreceptor neuropeptìdeo yy5
DE69920757D1 (de) Immunsuppressive wirkungen von pteridinderivaten
ATE269846T1 (de) N-substituierte aminotetraline als neuropeptid y y5 rezeptor-liganden und ihre anwendung zur behandlung von fettleibigkeit und anderen erkrankungen
SE0001899D0 (sv) New compounds
DE60104206D1 (de) Halbfeste arzneizubereitung enthaltend isotretinoin
BR0214343A (pt) Inibidores de 11 - beta - hidroxi esteróide desidrogenase tipo 1
MA29692B1 (fr) Derives de la xanthine en tant qu'agonistes selectifs du hm74a
EA200100872A1 (ru) Композиция валдекоксиба
HRP20060251A2 (en) Substituted oxasolidinones and their use
MA26709A1 (fr) Compositions pharmaceutiques de celecoxib, leurs procedes de preparation et methodes de traitement les utilisant
DE60134245D1 (de) (5-(2-hydroxy-4-chlorbenzoyl)valeriansäure und deren salze, und zusammensetzungen zur zuführung von wirkstoffen, die diese verbindungen enthalten
BR0114799A (pt) Compostos de ácido cianofenoxi carboxìlico e composições para liberar agentes ativos
YU49202A (sh) Benzazolski derivati i njihova upotreba kao modulatora jnk
BR0008687A (pt) Métodos para o tratamento de, e para prevenir ou controlar, distúrbios gastrointestinais, disfunção da motilidade gastrointestinal, emese, e doença de refluxo gastro-esofageano em um paciente, e, composição farmacêutica
MA29377B1 (fr) Derives de la pyrimidine pour traitement de troubles a caractere hyperproliferatif
MA27093A1 (fr) Derives de sulfonamides, leur preparation et leur application comme medicaments.
MA29213B1 (fr) Quinolones a substitution macrolones - amino
MA29723B1 (fr) Composes
MY120976A (en) 2-amino-6-(2-substituted-4-phenoxy)- substituted- pyridines
DE60141636D1 (de) Phospholipidderivate von valproinsäure und ihre kombinationen
WO2003017939A3 (fr) Composes de piperazinone utilises comme agents antitumoraux et anticancereux et procedes de traitement
WO2001091796A8 (fr) Methodes, composes et compositions permettant de traiter la goutte
DZ3459A1 (fr) Derives de 2h-1-benzopyran, procedes de preparation de ces derniers et compositions pharmaceutiques dans lesquels ils entrent.
WO2002069961A8 (fr) Medicaments-ligands du receptor il-8 destines a des maladies inflammatoires et auto-immunes